How do I calculate the Polymyxin B dose equivalent to 400,000 IU (4 lac IU) in milligrams per kilogram of body weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Polymyxin B Dosing: 400,000 IU Conversion

For Polymyxin B, 400,000 IU (4 lac IU) equals 50 mg, which translates to weight-based dosing of approximately 0.6-1.0 mg/kg/day for adults and up to 1.6 mg/kg/day for infants, divided into 2 doses.

Conversion Fundamentals

The critical conversion factor for Polymyxin B is: 1 mg = 10,000 IU 1. Therefore:

  • 400,000 IU = 40 mg of Polymyxin B sulfate
  • However, the FDA label specifies dosing in terms of Polymyxin B base activity

Standard Dosing by Age

Adults and Children (>2 years)

Intravenous administration: 15,000-25,000 units/kg/day 1

  • For a 70 kg adult: 1,050,000-1,750,000 IU/day (105-175 mg/day)
  • This should be divided into doses every 12 hours
  • Maximum daily dose: 25,000 units/kg/day 1

Your 400,000 IU dose represents approximately 5,700 units/kg for a 70 kg adult, which falls well within the therapeutic range but on the lower end.

Infants with Normal Renal Function

Up to 40,000 units/kg/day may be administered without adverse effects 1

  • For a 5 kg infant: up to 200,000 IU/day (20 mg/day)
  • Your 400,000 IU would represent 80,000 units/kg for this infant - exceeding recommended limits

Contemporary Evidence-Based Dosing

Recent guidelines from Asia recommend more aggressive dosing strategies 2, 3:

Loading dose: 2.5-5 mg CBA (colistin base activity)/kg/day divided into 2-4 doses 3

Maintenance dosing: Current evidence supports fixed maintenance doses of ≥150 mg/day or ≥2.5 mg/kg/day to achieve adequate probability of target attainment (≥90%) for organisms with MIC ≤2 mg/L 4

Critical Dosing Considerations

Renal Function Impact

  • Normal renal function: Standard dosing applies
  • Renal insufficiency (GFR <80 mL/min): Clearance decreases significantly (2.1 L/h vs 3.9 L/h), requiring dose reduction 5
  • CVVHD patients: Fixed dose of 100 mg q12h recommended; higher clearance observed but 22% dialysate recovery 5

Weight-Based vs Fixed Dosing

For patients weighing 45-90 kg, fixed dosing appears more appropriate than weight-based regimens 4. The population pharmacokinetic model demonstrates that body weight affects volume of distribution (impacting Cmax) but not clearance or overall exposure.

Practical Dosing Algorithm

  1. Calculate ideal dose:

    • Adults: 150-175 mg/day (1,500,000-1,750,000 IU/day) divided q12h
    • Pediatrics: 15,000-25,000 units/kg/day divided q12h
    • Infants: Up to 40,000 units/kg/day divided q12h
  2. Adjust for renal function:

    • CrCl >80: No adjustment needed
    • CrCl <80: Reduce maintenance dose by 30-40%
    • CVVHD: 100 mg q12h fixed dose
  3. Consider loading dose:

    • 200-300 mg (2-3 million IU) for critically ill patients 4, 5

Common Pitfalls

  • Unit confusion: Polymyxin B uses different units than colistin. For Polymyxin B: 1 mg = 10,000 units 1. For colistin: 1 million U = 33 mg CBA 2
  • Underdosing: 400,000 IU (40 mg) as a single dose is subtherapeutic for most adult infections
  • Ignoring renal function: Failure to adjust for renal insufficiency increases toxicity risk 5
  • Inadequate loading: Critically ill patients benefit from loading doses of 200-300 mg 4

Therapeutic drug monitoring is strongly encouraged given substantial inter-patient variability in clearance and volume of distribution 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.